Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors
Timothy A Yap, Li Yan, Amita Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2007
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing
Paula M Fracasso, Howard Burris, Matthew A Arquette, et al.
British Journal of Haematology
|
March 28, 2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
Taiga Nishihori, Todd J Alekshun, Kenneth Shain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
Beata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
Timothy A Yap, Li Yan, Amita Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2015
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Shivaani Kummar, Amit M Oza, Gini F Fleming, et al.
Academic Radiology
|
February 20, 2007
FDG-PET lymphoma demonstration project invitational workshop
Gary J Kelloff, Daniel M Sullivan, Wyndham Wilson, et al.
Research Square
|
May 5, 2025
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma
Rafael Renatino Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
Journal of the National Cancer Institute
|
June 19, 2013
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials
Jeffrey S Abrams, Margaret M Mooney, James A Zwiebel, et al.
Cancer Research
|
June 3, 2026
Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma
Rafael R Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors
Timothy A Yap, Li Yan, Amita Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2007
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing
Paula M Fracasso, Howard Burris, Matthew A Arquette, et al.
British Journal of Haematology
|
March 28, 2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
Taiga Nishihori, Todd J Alekshun, Kenneth Shain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
Beata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
Timothy A Yap, Li Yan, Amita Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2015
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Shivaani Kummar, Amit M Oza, Gini F Fleming, et al.
Academic Radiology
|
February 20, 2007
FDG-PET lymphoma demonstration project invitational workshop
Gary J Kelloff, Daniel M Sullivan, Wyndham Wilson, et al.
Research Square
|
May 5, 2025
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma
Rafael Renatino Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
Journal of the National Cancer Institute
|
June 19, 2013
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials
Jeffrey S Abrams, Margaret M Mooney, James A Zwiebel, et al.
Cancer Research
|
June 3, 2026
Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma
Rafael R Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
Page
of 9